

# Index

## A

- Academy of Managed Care Pharmacy, 88  
Adverse drug events (ADEs), 32–35, 91, 99, 100  
Ambulatory care  
  chain drugstores and, 166  
  formulary system and, 47–48  
  hospital pharmacy's role in, 154  
  implications in, 164  
  patient counseling in, 126–127  
  pharmaceutical prices and, 66–67  
  pharmaceutical services and, 9–10, 63  
American Association of Colleges of Pharmacy, 49, 88, 111, 132, 162  
American College of Clinical Pharmacy, 88, 132  
American Hospital Association, 51, 52  
*American Hospital Formulary Service*, 173, 176  
American Institute of the History of Pharmacy, 179  
American Medical Association, 51, 52, 56, 144  
American Nurses' Association, 144  
American Pharmaceutical Association, 51, 52, 88, 132, 162–164, 167–168, 174, 175  
American Society of Consultant Pharmacists, 88, 132, 167  
American Society of Health-System Pharmacists  
  challenges faced by, 153–156  
  changes brought by, 154–155  
  drug therapy management and, 90–91  
  evolution of, 148–150  
  expectations for future of, 152–153  
  guidelines on pharmaceutical services, 9–10  
  guidelines on quality assurance issues, 41  
  MedWatch program and, 94  
  member of FIP, 187  
  name change by, 154  
  objective of, 156  
  organizational issues of, 157  
  pharmacy organization merger issues and, 159–162  
  pharmacy technicians, 13–14  
  Pharm.D degree debate and, 107–110  
  plans for future of, 156–157  
  principles of, 150–151  
  role in clinical movement, 123–124  
  role in health-care reforms, 86, 88  
Apple, William S., 167, 174–176

## B

- Board certification, 110  
Board of Pharmaceutical Specialties, 49, 112

## C

- California pharmacist-prescribing project, 92  
Career management issues  
  for pharmacists, 104–141  
  lessons for success and, 138–139  
Chain drugstores, 1, 5, 108  
  pharmacy practice and, 165  
  role in educational requirements, 112  
Clinical pharmacy  
  career options in, 115–116  
  clinicians as subculture of pharmacy, 4  
  demographic factors in, 117–118  
  developing career ladders in, 119–120  
  hospital pharmacy and, 123  
  integration of, 121–122  
  media's attention toward, 124  
  medical profession's support for, 124–126  
  patient counseling and, 126–128  
  pharmaceutical care and, 129–131  
  problems associated with, 121  
  role in pharmacy's transformation, 26–27  
Clozapine (Clozaril), 72  
Coalition for Consumer Access to Pharmaceutical Care, 88, 89  
Community pharmacies, 1, 2, 63  
  Merck-Medco merger and, 64–65  
  pharmaceutical prices and, 66–67

  pharmacists' education requirements and, 108

- Corporate control  
  in health care delivery, 20–21  
  of pharmacies, 5–6  
Cost containment issues  
  health care delivery and, 18–19  
  hospital executives and, 45–46  
  hospital pharmacy and, 43–44  
  managed-care plans and, 47–48  
  price controls, pharmaceuticals, 67

## D

- Deaths  
  caused by contaminated sterile products, 40  
  caused by medication errors, 36–38  
Developing countries, pharmacists in, 188–189  
Directions for Clinical Practice in Pharmacy (conference), 7  
Disease-state management, 63  
Drug abuse  
  pharmacists' role in preventing, 193  
  rational policies toward, 190–191  
Drug companies. *See* Pharmaceutical industry  
Drug distribution systems  
  pharmaceutical industry and, 72–73  
  pharmacists' role in, 111–112  
  reasons for safeguarding, 76  
Drug product selection, 52, 54  
Drug therapy management  
  clinical movement and, 123  
  formulary system and, 47–49  
  optimal use of, 45  
  pharmacists' role in, 57–58, 74–75, 90–91, 130–131  
  therapeutic interchange and, 54  
Drug-use control  
  by pharmacists, 38–39  
  cost containment issues and, 43–44  
  defined, 44  
  drug abuse and, 190–191  
Durham–Humphrey Amendment, 172

## E

- Educational requirements  
  chain stores and, 112  
  debate about entry-level, 107–109, 109–111, 162  
  Task Force on Pharmacy Education report on, 113–114

## F

- Facilities planning of hospital pharmacy, 30–31  
Food and Drug Administration, 36, 54, 72  
  MedWatch program and, 94  
  postmarketing restrictions on drugs and, 95–96  
  role in pharmaceuticals promotion, 78  
Food, Drug, and Cosmetic Act, 172  
Formulary system  
  drug therapy and, 47–49  
  elements of, 51–52  
  pharmaceutical prices and, 69  
  pharmacoeconomic issues and, 62  
  therapeutic interchange and, 54–57  
Franco, Donald E., 151, 172–174, 176–177, 187

## G

- Gans, John A., 162–164  
Generic substitution, 52, 54, 55  
Geriatric population, medication errors and, 37  
Group purchasing, 59–61, 63

## H

- Harrison Narcotic Act, 191  
Health care delivery  
  dissatisfaction with, 20–21  
  nuclear war issues and, 144–145  
  pharmaceutical care and, 135  
  transformations in, 18–19

understanding trends in, 138

Health-care reforms

- Congressional speech on, 84–85
- goals for, 80–82
- pharmaceutical prices and, 66–67
- pharmacists' role in, 82–84
- pharmacists and, 88–89
- reasons for failure of, 86–87

Homelessness, mental health problems and, 192

Hospital pharmacy. *See also* Clinical pharmacy

- ambulatory care by, 154
- career options in, 139
- clinical services integration in, 121–122
- cost containment issues and, 43–44, 49
- drug product preparation by, 35
- drug-use control by, 38–39
- elevating status of, 45–46
- facilities planning of, 30–31
- hallmarks of, 6
- leadership priorities for, 18–20
- managed-care plans and, 181
- managers' status in, 28
- Merck-Medco merger and, 64–65
- postgraduate training and, 11–13
- priorities for, 122–124
- process for change in, 141
- technicians in, 170

Hospitals

- group purchasing by, 59–61, 63
- marketing pharmaceuticals to, 58, 62–63
- pharmaceutical services in, 166
- preventing drug-induced illness in, 32–34
- resale of pharmaceuticals by, 76
- role in improving pharmacists' image, 97–98

Humphrey, Hubert H., 171–172

---

### I

Information technology, prescription dispensing and, 21

Integrated health-care systems. *See* Managed-care plans

*International Pharmaceutical Abstracts*, 173

International Pharmaceutical Federation, 173, 186

Inventory, virtual, 63

---

### J

Joint Commission of Pharmacy Practitioners, 73, 131, 132, 150, 151, 160, 183

---

### L

Large volume parenteral therapy, 40

Leadership issues

- ASHP and, 151
- facilities planning issues and, 30–31
- for hospital pharmacies, 18–20
- for pharmacy departments, 26–27, 45–46
- for pharmacy practice, 22–23

---

### M

Mail-order pharmacies, 1

Managed-care plans

- ambulatory care for enrollees of, 9
- ASHP and, 155
- challenges faced by pharmacies in, 22
- corporate control and, 5
- formulary system in, 47–48
- hospital pharmacy and, 181
- marketing pharmaceuticals to, 58, 62–63, 71
- pharmacy success factors for, 19
- therapeutic interchange issues and, 54–56

Managers

- characteristics of successful, 29
- clinical pharmacists and, 119–120
- opportunities for contributions by, 48–49
- role in preventing medication errors, 35
- role in transforming pharmacies, 46
- status in hospital pharmacy, 28

Marketing by pharmaceutical industry, 58, 62–63

Medication errors. *See also* Adverse drug events (ADEs)

- deaths caused by, 36–37
- drug-use control and, 38–39

- pharmaceutical care and, 135–137
- prevention of, 34–35, 138–139
- quality assurance issues and, 35–36
- reforms to avoid, 37–38
- trouble-shooter, 39

Mental health problems, 192

Merck-Medco merger, 1, 64–65

Millis Commission, The, 33

---

### N

National Association of Chain Drug Stores, 163, 164, 165

National Association of Retail Druggists, 167

National Conference of Catholic Bishops, 144

National Consumers League, 88

National Pharmaceutical Association, 88

Nuclear war issues, 143–145

---

### O

Oddis, Joseph, 176, 186, 187

Operation Desert Storm, 184

---

### P

Patient(s)

- ambulatory, 9–10
- communication between pharmacists and, 6, 101–102
- counseling, 126–128
- death by contaminated sterile products, 40
- death by medication errors, 36–38
- education about medications, 21, 129–131
- pediatric, medication errors, 36–37
- pharmaceutical care and, 133–135
- risk for complications, identifying, 33
- safety issues, 19

Persian Gulf War, 184–186

Pharmaceutical care

- ASHP's future and, 153–155
- clinical, 123, 129–131
- defined, 129–131
- drug misadventure problems and, 135–137
- for ambulatory patients, 9–10
- fundamentals of, 133–134
- goal of, 63
- in hospitals vs. chain drugstores, 166
- managed-care pharmacy and, 48
- pharmacists' contract with America and, 25
- pharmacy practice mission and, 131–133
- public health programs and, 94–95
- ways to encourage, 134
- working on advancing, 19–20

Pharmaceutical industry

- buyouts and mergers in, 182
- drug distribution systems and, 72–73
- drug-therapy monitoring and, 74–75
- marketing by, 58, 62–63
- Merck-Medco merger and, 64–65
- pharmaceutical prices and, 66–70
- pharmaceuticals' promotion by, 71, 77–79
- recruitment by, 140
- therapeutic interchange and, 55–57

Pharmaceutical prices

- criticism about, 68
- drug distribution system and, 72–74
- ethical issues related to, 76–79
- factors deciding, 68–69
- health care reforms and, 66–67
- Merck-Medco merger and, 64–65

Pharmaceuticals

- group purchasing of, 59–61, 63
- marketing of, 62–63
- Medicaid program for, 105
- postmarketing restrictions on, 95–96
- promotion of, 70–71, 77–79
- resale of, 76

Pharmacists. *See also* Educational requirements

- ambulatory-care, 9–10
- autonomy, 145–147
- career management issues for, 140–141
- chain drugstores' behavior toward, 165
- communication between patients and, 6, 101–102

- developing countries, 188–189
  - dispenser as pharmacy subculture, 4
  - dispenser–communicator as pharmacy subculture, 4
  - drug-use control by, 38–39, 44
  - entrepreneur as pharmacy subculture, 4
  - erasing stereotype image of, 102–104
  - expectations for, 119–120
  - health-care reforms and, 81, 88–89
  - job dissatisfaction among, 28
  - leadership issues, 22–23
  - lessons for success for, 138–139
  - manager–administrator as pharmacy subculture, 4
  - manager–leader as pharmacy subculture, 4
  - mission, gaining support for, 99–100
  - patient counseling reassessment by, 126–128
  - Pharm.D degree debate and, 107–109, 112, 113
  - postgraduate training for, 11–13
  - postmarketing restrictions on drugs and, 95–96
  - practitioners vs. providers, 1–3, 159
  - role as prescriber, 92–93
  - role in drug therapy management, 57–58, 74–75, 90–91
  - role in influencing prescriber behavior, 57–59
  - role in medication-system reforms, 37–38
  - role in Persian Gulf War, 184–186
  - role in pharmaceutical promotion, 70–71
  - role in preventing drug abuse, 193
  - role in preventing drug-induced illness, 32–36
  - role in resale of pharmaceuticals, 76
  - shortage of, 182
  - teaching patients, 21
  - therapeutic interchange and, 53–55
  - time management issues for, 141–143
  - ways to improve image of, 97–98
  - Pharmacy benefit managers (PBMs), 56, 57
  - Pharmacy departments
    - challenges faced by, 22
    - clinical services approaches used by, 116
    - elevating status of, 45–46
    - facilities planning, 30–31
    - leadership issues related to, 26–27
    - role in improving pharmacists' image, 101–102
    - role in preventing drug-induced illness, 33–34
  - Pharmacy organization(s)
    - chain drugstores and, 165–166
    - consolidation of, 159–161
    - foundation organization, relevance, 167–168
    - role in elevating pharmacy profession, 162–164
    - technicians in, 169–170
    - unity, 161–162
  - Pharmacy practice
    - ASHP's role in elevating, 151–152
    - chain drugstores and, 165
    - mission statement of, 132–133
    - needs of, 149
  - Pharmacy profession, 2
    - achieving full potential of, 7–8
    - APhA's role in elevating, 162–164
    - clinical movement of, 26–27
    - corporate control of, 5–6
    - cultures and subcultures of, 3–4
    - demographics and clinical careers in, 117–118
    - developing career ladders in, 119–120
    - goal of, 7, 136, 147
    - health-system practice, 148–150
    - history, 178–180
    - in developing countries, 188–189
    - inaccurate perceptions about, 104–106
    - integrating clinical pharmacy into, 115–116
    - mail order, 1
    - major happenings in 1980s in, 180–184
    - managed-care, 47–48
    - managing workers in, 28
    - Merck-Medco merger and, 64–65
    - mission of, 131–133, 183
    - opportunities for advancement, 48–49
    - outpatient, 10
    - paradigm shift in, 21
    - professional imperative, 22–23
    - role in handling public health issues, 103–104
    - role in health-care reforms, 82–84
    - role in society, 111–112
    - technical personnel status in, 13–15
    - technicians' role in, 169–170
    - transforming, 46
  - Pharmacy providers, 1–3, 159
  - Pharmacy technicians
    - in pharmacy organizations, 169–170
    - issues related to, 15–17
    - need and training for, 123
    - role of, 169
    - status, 13–15
  - Pharm.D degree
    - debate about, 107–109, 112
    - entry-level vs. advanced degree, 110, 113, 162
    - types of, 109
  - Physicians
    - drug misadventure problems and, 136
    - pharmacists' role in influencing, 57–59
    - support for clinical pharmacy, 124–126
  - Prescription Drug Marketing Act, 76
  - Provost, George P., 176–177
  - Public health issues/programs
    - pharmaceutical care and, 94–95
    - pharmacists' role in handling, 103–104
  - Public policy
    - ASHP and, 151
    - drug therapy management and, 90–91
    - health-care reforms and, 80–82, 84–87
    - pharmacists as prescriber and, 92–93
    - pharmacy's role in, 82–84, 88–89
    - postmarketing restrictions on drugs and, 95–96
    - public health programs and, 94–95
- 
- Q**
- 
- Quality assurance issues
    - medication errors and, 35–36
    - sterile products and, 40–41
- 
- R**
- 
- Residency training
    - ASHP's role in addressing, 151
    - challenges and opportunities, 12–13
    - for pharmacists, 11–13
  - Robinson-Patman Act, 76
- 
- S**
- 
- Safety issues
    - drug-induced illness and, 32–34
    - drug-use control and, 44
    - hospital cutbacks and, 19
    - medication errors and, 34–36
    - sterile products and, 40–41
  - Schlegel, John F., 167
  - Specialty certification, 110
  - Standards of practice, 6
  - Sterile products, 40–41
  - Subcultures of pharmacy, 3–4
- 
- T**
- 
- Task Force on Pharmacy Education, 113, 114
  - Therapeutic interchange
    - rise of, 55–57
    - understanding, 53–55
  - Third World, pharmacists in, 188–189
  - Time management issues, 141–143
- 
- W**
- 
- World Health Organization (WHO), 188, 189
- 
- Z**
- 
- Ziegler, Ronald, 164–166